Griffin Chris, Locke Salina, Montiani-Ferreira Fabiano, Lopes Grego Andressa, Soto Jeny, Cray Carolyn
Griffin Avian & Exotic Veterinary Hospital, Kannapolis, NC 28083, USA.
Avian and Exotic Animal Care, Raleigh, NC 27617, USA.
Animals (Basel). 2024 Oct 19;14(20):3029. doi: 10.3390/ani14203029.
A recombinant vaccine for rabbit hemorrhagic disease virus 2, a highly pathogenic virus, was granted emergency use authorization in the United States after the detection and spread of the virus starting in 2018. The goal of the current study was to assess pet rabbits (n = 29) through physical examination and routine clinical pathology testing using repeated assessments post-vaccination. In addition, seroconversion was also monitored after the initial vaccination and booster vaccination. Neither owners nor clinicians detected any physical abnormalities in relationship to the vaccine protocol. Hematological and clinical biochemistry testing showed some changes although median values were within species specific reference intervals. A significant increase in antibody levels was observed at day 21 (post-initial vaccination) and day 49 (post-booster vaccination) versus that present at baseline ( < 0.0001). However, variability in study rabbits was noted with some individuals showing low antibody levels as well as a lower overall response in older rabbits (r = -0.56, = 0.006). A second cohort of rabbits was assessed at 11-12 months post-initial vaccination. In this second group, antibody levels were not significantly different from baseline levels ( = 0.21). Additional studies should be conducted to further define the variability in seroconversion and the term of protection in pet rabbits as the industry moves forward in the optimization of RHDV2 vaccines.
2018年开始检测到兔出血症病毒2（一种高致病性病毒）并传播后，一种针对该病毒的重组疫苗在美国获得了紧急使用授权。本研究的目的是通过体格检查和常规临床病理检测，对29只宠物兔进行接种后重复评估。此外，还在初次接种和加强接种后监测血清转化情况。主人和临床医生均未发现与疫苗接种方案相关的任何身体异常。血液学和临床生化检测显示出一些变化，尽管中位数在物种特定参考区间内。与基线水平相比，在第21天（初次接种后）和第49天（加强接种后）观察到抗体水平显著升高（<0.0001）。然而，研究兔存在变异性，一些个体抗体水平较低，老年兔的总体反应也较低（r = -0.56， = 0.006）。在初次接种后11 - 12个月对另一组兔子进行了评估。在这第二组中，抗体水平与基线水平无显著差异（ = 0.21）。随着该行业在优化兔出血症病毒2疫苗方面不断前进，应开展更多研究以进一步明确宠物兔血清转化的变异性和保护期限。
